Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Discovery of 2-[1-(4,4-Difluorocyclohexyl)piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide (NMS-P118): A Potent, Orally Available, and Highly Selective PARP-1 Inhibitor for Cancer Therapy
Gianluca Papeo, Helena Posteri, Daniela Borghi, et al.
Journal of Medicinal Chemistry (2015) Vol. 58, Iss. 17, pp. 6875-6898
Closed Access | Times Cited: 121

Showing 26-50 of 121 citing articles:

Design, synthesis, and biological evaluation of quinazolin-4(3H)-one derivatives co-targeting poly(ADP-ribose) polymerase-1 and bromodomain containing protein 4 for breast cancer therapy
Xiaosa Chang, Dejuan Sun, Danfeng Shi, et al.
Acta Pharmaceutica Sinica B (2020) Vol. 11, Iss. 1, pp. 156-180
Open Access | Times Cited: 55
Synthesis of new substituted pyridine derivatives as potent anti-liver cancer agents through apoptosis induction: In vitro, in vivo, and in silico integrated approaches
Ahmed T. A. Boraei, Elsayed H. Eltamany, Imran Ali, et al.
Bioorganic Chemistry (2021) Vol. 111, pp. 104877-104877
Closed Access | Times Cited: 55
Evaluation of inhibitory effects of some novel phenolic derivatives on the mushroom tyrosinase activity: Insights from spectroscopic analyses, molecular docking and in vitro assays
Atiyeh Mahdavi, Nahid Mohammadsadeghi, F. Mohammadi, et al.
Food Chemistry (2022) Vol. 387, pp. 132938-132938
Closed Access | Times Cited: 33
Enabling drug discovery for the PARP protein family through the detection of mono-ADP-ribosylation
Alvin Lu, Ryan Abo, Yue Ren, et al.
Biochemical Pharmacology (2019) Vol. 167, pp. 97-106
Open Access | Times Cited: 46
Bridging of nucleosome-proximal DNA double-strand breaks by PARP2 enhances its interaction with HPF1
Guillaume Gaullier, Genevieve Roberts, Uma M. Muthurajan, et al.
PLoS ONE (2020) Vol. 15, Iss. 11, pp. e0240932-e0240932
Open Access | Times Cited: 43
Selective PARP1 inhibitors, PARP1-based dual-target inhibitors, PROTAC PARP1 degraders, and prodrugs of PARP1 inhibitors for cancer therapy
Xiaopeng Peng, Wanyi Pan, Feng Jiang, et al.
Pharmacological Research (2022) Vol. 186, pp. 106529-106529
Closed Access | Times Cited: 24
PARP-1: a critical regulator in radioprotection and radiotherapy-mechanisms, challenges, and therapeutic opportunities
Wenhao Li, Fei Wang, Gui-yuan Song, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 15
Discovery of quinazoline-2,4(1H,3H)-dione derivatives as novel PARP-1/2 inhibitors: design, synthesis and their antitumor activity
Jie Zhou, Ming Ji, Haiping Yao, et al.
Organic & Biomolecular Chemistry (2018) Vol. 16, Iss. 17, pp. 3189-3202
Closed Access | Times Cited: 43
Discovery of Stereospecific PARP-1 Inhibitor Isoindolinone NMS-P515
Gianluca Papeo, Paolo Orsini, Nilla Avanzi, et al.
ACS Medicinal Chemistry Letters (2019) Vol. 10, Iss. 4, pp. 534-538
Open Access | Times Cited: 36
A ribose-functionalized NAD+ with unexpected high activity and selectivity for protein poly-ADP-ribosylation
Xiaonan Zhang, Qinqin Cheng, Jingwen Chen, et al.
Nature Communications (2019) Vol. 10, Iss. 1
Open Access | Times Cited: 36
Discovery of Novel Apigenin–Piperazine Hybrids as Potent and Selective Poly (ADP-Ribose) Polymerase-1 (PARP-1) Inhibitors for the Treatment of Cancer
Huan Long, Xiaolong Hu, Baolin Wang, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 16, pp. 12089-12108
Closed Access | Times Cited: 31
Structure-based design, synthesis, and evaluation of inhibitors with high selectivity for PARP-1 over PARP-2
Yu Jiang, Lingling Luo, Tong Hu, et al.
European Journal of Medicinal Chemistry (2021) Vol. 227, pp. 113898-113898
Closed Access | Times Cited: 30
Existing Evidence for the Repurposing of PARP-1 Inhibitors in Rare Demyelinating Diseases
Marianna Mekhaeil, Kumlesh K. Dev, Melissa J. Conroy
Cancers (2022) Vol. 14, Iss. 3, pp. 687-687
Open Access | Times Cited: 20
A multi-task FP-GNN framework enables accurate prediction of selective PARP inhibitors
Daiqiao Ai, Jingxing Wu, Hanxuan Cai, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 19
Current status and future promise of next-generation poly (ADP-Ribose) polymerase 1-selective inhibitor AZD5305
Jingcao Zheng, Zhengyu Li, Wenjiao Min
Frontiers in Pharmacology (2023) Vol. 13
Open Access | Times Cited: 13
Discovery of Quinazoline-2,4(1H,3H)-dione Derivatives Containing a Piperizinone Moiety as Potent PARP-1/2 Inhibitors─Design, Synthesis, In Vivo Antitumor Activity, and X-ray Crystal Structure Analysis
Jie Zhou, Tingting Du, Xiaoyu Wang, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 20, pp. 14095-14115
Closed Access | Times Cited: 11
Advances in Development of Selective Antitumor Inhibitors That Target PARP-1
Fang Liu, Jia‐Shu Chen, Xiangqian Li, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 24, pp. 16464-16483
Closed Access | Times Cited: 11
A PARP2 active site helix melts to permit DNA damage-induced enzymatic activation
Emily S Smith-Pillet, Ramya Billur, Marie-France Langelier, et al.
Molecular Cell (2025)
Closed Access
Impact of a Cancer-Associated Mutation on Poly(ADP-ribose) Polymerase1 Inhibition
Naga Shanmugam, Shubham Chatterjee, G. Andrés Cisneros
The Journal of Physical Chemistry B (2025)
Open Access
Duplexed CeTEAM drug biosensors reveal determinants of PARP inhibitor selectivity in cells
Maria João Pires, Seher Alam, Alen Lovrić, et al.
Journal of Biological Chemistry (2025), pp. 108361-108361
Open Access
Engaging an engineered PARP-2 catalytic domain mutant to solve the complex structures harboring approved drugs for structure analyses
Xiaoyu Wang, Jie Zhou, Bailing Xu
Bioorganic Chemistry (2025), pp. 108471-108471
Closed Access
Cytotoxic activity, caspase-3 mediated apoptosis, and PARP-1 inhibition targeted molecular modeling studies of novel imidazole-fused hydrazones
Michael Tapera, Muhammed Tılahun Muhammed, Yalçın Erzurumlu, et al.
Journal of Molecular Liquids (2025), pp. 127637-127637
Closed Access
Joining of DNA breaks- interplay between DNA Ligases and Poly (ADP-ribose) polymerases
Nicolas Call, Alan E. Tomkinson
DNA repair (2025), pp. 103843-103843
Closed Access
Discovery of 2-substituted 1 H -benzo[ d ]immidazole-4-carboxamide derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors with in vivo anti-tumor activity
Jie Zhou, Ming Ji, Zhixiang Zhu, et al.
European Journal of Medicinal Chemistry (2017) Vol. 132, pp. 26-41
Closed Access | Times Cited: 37
Chemical Proteomics Approach for Profiling the NAD Interactome
Justina Šileikytė, Sunil K. Sundalam, Larry L. David, et al.
Journal of the American Chemical Society (2021) Vol. 143, Iss. 18, pp. 6787-6791
Open Access | Times Cited: 26

Scroll to top